Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

Stock Information for Aptorum Group Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aptorum Group Limited

Andean Precious Metals Reports Q4/FY 2023 Results; Meets 2023 Revised Production Guidance
Marcos Holanda Joins Andean Precious Metals as Chief Operating Officer
Andean Precious Metals Announces Q4/FY 2023 Earnings Conference Call and Webcast
Andean Precious Metals Announces Filing of Articles of Continuance
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
Andean Precious Metals' Subsidiary Secures $25 Million Revolving Line of Credit
Andean Precious Metals Files NI 43-101 Technical Report for San Bartolome
Andean Precious Metals Announces Stock Option Grant

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.